A Phase II Study of Bevacizumab + Sorafenib in Metastatic Breast Cancer

Inclusion Criteria: * Histologic or cytologic diagnosis of breast cancer with evidence of metastatic disease. NOTE: Patients with Her-2 positive (3+ by IHC or gene amplification by FISH) are eligible only if they have had prior trastuzumab therapy. * Must have measurable or non-measurable lesions as defined by the Response Evaluation Criteria in Solid Tumors (RECIST). * Two or fewer prior chemotherapy regimens in any disease setting. NOTE: All adjuvant and neoadjuvant chemotherapy will be considered one regimen. NOTE: Prior hormonal therapy for metastatic disease is allowed. NOTE: Prior radiation therapy is allowed as long as the irradiated area is not the only source of evaluable disease. * Age \> 18 years at the time of consent. * Written informed consent and HIPAA authorization for release of personal health information. * Females of childbearing potential and males must be willing to use an effective method of contraception (hormonal or barrier method of birth control; abstinence) from the time consent is signed until 8 weeks after treatment discontinuation. * Females of childbearing potential must have a negative pregnancy test within 7 days prior to being registered for protocol therapy. * Ability to comply with study and/or follow-up procedures. Exclusion Criteria: * No prior therapy with bevacizumab, sorafenib or any other known VEGF inhibitors. * No known hypersensitivity to any component of the study drugs. * No other forms of cancer therapy including radiation, chemotherapy and hormonal therapy within 21 days prior to being registered for protocol therapy. * No history or radiologic evidence of CNS metastases including previously treated, resected, or asymptomatic brain lesions or leptominigeal involvement. A head CT or MRI must be obtained within 28 days prior to being registered for protocol therapy. * No other participation in another clinical drug study within 28 days prior to being registered for protocol therapy. * No known human immunodeficiency virus (HIV) infection or chronic Hepatitis B or C * No major surgical procedure within 28 days prior to being registered for protocol therapy or anticipation of need for major surgical procedure during the course of the study. Placement of a vascular access device and breast biopsy will not be considered major surgery. * No minor surgical procedure within 7 days prior to being registered for protocol therapy. * No known history of cerebrovascular disease including TIA, stroke or subarachnoid hemorrhage. * No known history of ischemic bowel. * No known history of deep venous thrombosis or pulmonary embolism. * No history of hypertensive crisis or hypertensive encephalopathy. * No non-healing wound or fracture. * No active infection requiring parenteral antibiotics. * No other hemorrhage/bleeding event ≥ CTCAE grade 3 within 28 days prior to being registered for protocol therapy.